EL DORADO HILLS, Calif.--(BUSINESS WIRE)--April 25, 2005--- PhereSys Therapeutics Corporation announced today the establishment of its Midwest Regional therapeutic apheresis (TA) operations based in Chicago and Minneapolis. Patricia Golden, BSN, RN and Christine Fernandez, BSN, RN have been appointed Vice Presidents and Co-Regional Directors and bring over 40 years of combined experience in therapeutic apheresis ('TA") to the Company. The opening of the Midwest region is a part of the Company's strategic plan to build the nation's most comprehensive, contract mobile TA network.
Ms. Golden was responsible for the development of the therapeutic apheresis program at Kidney Disease and Critical Care Associates serving the Minneapolis and St. Paul areas, which grew to more than 1,500 procedures per year. After Fresenius Medical Care of North America (FMC-NA) assumed control of the program, she advanced to the position of Corporate Director of Therapeutic Apheresis. Currently, Ms. Golden is the President of the American Society of Apheresis (ASFA), an organization specializing in the training and education of apheresis practitioners. Ms. Golden has conducted numerous educational programs on therapeutic apheresis and has authored and co-authored a number of journal articles. She is active in several professional societies, and has committee appointments to the American Society for Clinical Pathology (ASCP) Globalization Task Force, ASFA Public Affairs Committee, ASFA Allied Health Committee, and the American Society for Hematology, Committee on Practice. Ms. Golden has been Chair of the ASFA/ASCP Hemapheresis Practitioner Certification Examination Committee for three years. She is also the ASFA liaison to the ASCP Board of Registry, Board of Governors.
